7 completed, 7 unknown, 2 enrolling by invitation, 1 active not recruiting. 3 Phase 1, 3 Phase 2, 3 Phase 4, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 2, Recruiting 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 4 | 3 | Completed 1, Enrolling by invitation 1, Withdrawn 1 |
| Not applicable | 2 | Unknown 2 |
Follow Liver Transplant Rejection: new trials by email Literature Review of Liver Transplant Rejection trials Research Report on Liver Transplant Rejection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver - Liver Diseases, Liver Cancer | Phase 1 / Phase 2 | Recruiting | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | 90 | 2025-06-01 | 2025-07-08 |
| Safety of DNP007 in Healthy Subjects DNP007 - Liver Transplant Rejection, Liver Transplant; Complications | Phase 1 | Unknown | Seoul National University Hospital | 12 | 2024-06-10 | 2024-06-18 |
| Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients Prograf, Envarsus - Liver Transplant Rejection, Immune System Suppression | Phase 4 | Enrolling by invitation | University Health Network, Toronto | 40 | 2024-01-01 | 2024-12-11 |
| Long-term Benefit of MPA in Liver Transplantation enteric-coated mycophenolate (MPAs), None MPA - Liver Transplant Rejection, Immunosuppressant Adverse Reaction | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 500 | 2022-12-04 | 2023-02-01 | |
| TRU-IMMUNO: Optimizing Liver Immunosuppression Patients monitored with TruGraf and TRAC Liver testing - Liver Transplant Rejection | Unknown | Transplant Genomics, Inc. | 130 | 2022-05-01 | 2022-05-02 | |
| Global Utilization And Registry Database for Improved preservAtion of doNor Livers LIVERguard - Liver Diseases, Liver Dysfunction | Enrolling by invitation | Paragonix Technologies | 2000 | 2022-03-15 | 2026-09-17 | |
| Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients Erythropoietin - Liver Transplant Rejection | Phase 4 | Completed | Northwestern University | 9 | 2022-02-18 | 2026-10-29 |
| VOCs in Kidney and Liver Transplants Breath analysis - Liver Transplant Rejection, Kidney Transplant; Complications | Not applicable | Unknown | Societa Italiana di Chirurgia ColoRettale | 100 | 2021-10-02 | 2021-04-20 |
| Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. gene polymorphism - Liver Transplant Rejection | Completed | Helwan University | 105 | 2021-03-15 | 2023-09-29 | |
| Mortality, Morbidity and Risk Factors of Liver Retransplantation Liver Transplantation - Liver Transplant; Complications, Liver Transplant Rejection | Completed | Memorial Bahçelievler Hospital | 32 | 2021-03-10 | 2021-12-06 | |
| The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma Tacrolimus, Unbound tacrolimus measurement, CYP3A4 and CYP3A5 genotyping - Immunosuppression, Kidney Transplant Rejection | Unknown | National Science Centre, Poland | 380 | 2020-08-01 | 2022-04-22 | |
| Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension CFZ533, Tacrolimus - MMF - corticosteroids - Liver Transplant Rejection | Phase 2 | Terminated | Novartis Pharmaceuticals | 129 | 2019-10-07 | 2025-05-16 |
| Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients N/A-Observational Study - Liver Transplant Rejection, Liver Transplant Failure and Rejection | Active not recruiting | St. Louis University | 70 | 2019-04-16 | 2025-12-10 | |
| Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects Budesonide, Tacrolimus（FK506）, Mycophenolate Mofetil - Acute Cellular Graft Rejection, Liver Transplant Rejection | Phase 4 | Withdrawn | Montefiore Medical Center | 2019-01-01 | 2019-09-23 | |
| Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial Envarsus, Advagraf - Liver Transplant Rejection, Immunosuppression | Not applicable | Unknown | Medical University of Warsaw | 200 | 2018-07-09 | 2018-07-27 |
| The TOGETHER Project - Liver Liver Transplant - Liver Transplant Rejection | Completed | Mayo Clinic | 54 | 2017-03-15 | 2022-05-20 | |
| MSC Therapy in Liver Transplantation Mesenchymal Stromal Cells - Liver Transplant Rejection | Phase 1 | Unknown | Monia Lorini | 20 | 2014-10-01 | 2018-04-06 |
| Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation Liver Transplant Rejection | Completed | Yonsei University | 48 | 2011-04-01 | 2015-01-27 | |
| Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments. - Liver Transplant Rejection | Phase 2 | Completed | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | 13 | 2011-03-01 | 2015-12-14 |
| Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents Blood Draw - Rapamycin, Blood Draw from Control Subjects, Blood Draw - CyA - Liver Transplant Rejection, Immunosuppression | Completed | Northwestern University | 31 | 2007-09-01 | 2015-04-15 |
Liver Diseases (3) · Rejection, Psychology (3) · Liver Cirrhosis (2) · Liver Failure (2) · Diabetes Mellitus (1) · Fatty Liver (1) · Genetic Predisposition to Disease (1) · Hypertension (1) · Infections (1) · Liver Neoplasms (1) · Non-alcoholic Fatty Liver Disease (1) · Renal Insufficiency (1)
Digestive System Diseases (4) · Behavior (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Social Behavior (3) · Fibrosis (2) · Hepatic Insufficiency (2) · Cardiovascular Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Disease Susceptibility (1) · Endocrine System Diseases (1) · Fatty Liver (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Tacrolimus (5) · Mycophenolic Acid (2) · Budesonide (1) · Cyclosporine (1) · Erythropoietin (1) · Liver Transplantation (1) · Polymorphism, Genetic (1) · Prednisone (1) · Sirolimus (1) · iscalimab (1)
Northwestern University (2) · AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC (1) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1) · Helwan University (1) · Mayo Clinic (1) · Medical University of Warsaw (1) · Memorial Bahçelievler Hospital (1) · Monia Lorini (1) · Montefiore Medical Center (1) · National Science Centre, Poland (1) · Novartis Pharmaceuticals (1) · Paragonix Technologies (1) · Seoul National University Hospital (1) · Societa Italiana di Chirurgia ColoRettale (1) · St. Louis University (1)
United States (6) · Italy (3) · China (2) · Poland (2) · South Korea (2) · Spain (2) · Argentina (1) · Belgium (1) · Canada (1) · Czechia (1) · Egypt (1) · France (1) · Germany (1) · Hungary (1) · Netherlands (1)
Josh Levitsky, MD (2) · Ajay Jain, MD (1) · Alessandro Rambaldi, MD (1) · Antonio Galindo, MD (1) · Antonio Pinna, MD (1) · Arcangelo Picciariello, MD (1) · Claudio Velati, MD (1) · Daniel Garrote, MD (1) · Francisco Javier Padillo, MD (1) · Giuseppe Remuzzi, MD (1) · Jason Vanatta, MD (1) · Mark Stegall, MD (1) · Martino Introna, MD (1)
PMID 20600032, PMID 26932352, PMID 29485508, PMID 33370477
2009 (1), 2014 (1), 2018 (1)